New Releases from NCBI BookshelfSacituzumab Govitecan (Trodelvy): CADTH Reimbursement Review: Therapeutic area: HR-positive, HER2-negative advanced or metastatic breast cancer [Internet].Sacituzumab Govitecan (Trodelvy): CADTH Reimbursement Review: Therapeutic area: HR-positive, HER2-negative advanced or metastatic breast cancer [Internet].